Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating Costs and Expenses:
General and administrative	$ 1,713	$ 1,122
Research and development	6,494	2,717
Total Operating Costs and Expenses	8,207	3,839
Loss from Operations	(8,207)	(3,839)
Other Income (Expense):
Change in fair value of warrant liability	(4,152)	0
Interest income	1	1
Total Other Income (Expense)	(4,151)	1
Net Loss	(12,358)	(3,838)
Net Loss Attributable to Non-controlling Interest	0	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (12,358)	$ (3,838)
Net Loss Per Share - Basic and Dilutive (in dollars per share)	$ (0.17)	$ (0.07)
Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries (in dollars per share)	$ (0.17)	$ (0.07)
Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)	72,673,959	58,324,260